002644.SZ Stock Analysis
00
Neutral
Based on Eyestock quantitative analysis, 002644.SZ`s fundamental data and valuation indicate an investment grade of Neutral at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly undervalued
Lanzhou Foci Pharmaceutical Co., Ltd. engages in raw material research, modern formulations production, and extraction of traditional chinese medicine. The company is headquartered in Lanzhou, Gansu and currently employs 1,295 full-time employees. The company went IPO on 2011-12-22. The Company’s main products are categorized into pills, tablets, granules, syrups, capsules, glue and others, including Liuwei Dihuang pills, Xiaoyao Pill, Xiangsha Yangwei pills, ginseng Gubeng Huanhao pills and other Chinese patent drugs, as well as large health products, such as Ejiao and Ejiao loafs. The firm distributes its products under the brand names Foci, Baolu and Mianshan. The firm is also involved in the cultivation, processing and marketing of Chinese herbal medicine. The firm distributes its products in domestic market and to overseas markets.